Breaking News Instant updates and real-time market news.

BHC

Bausch Health

$25.33

0.235 (0.94%)

08:10
02/13/19
02/13
08:10
02/13/19
08:10

Bausch Health's Bausch+Lomb granted 510(k) clearance for Hydra-PEG contact lens

Bausch Health's wholly owned subsidiary Bausch + Lomb has received 510(k) clearance for use of the Tangible Hydra-PEG custom contact lens coating technology with some of its Boston gas permeable materials. Designed to address contact lens discomfort and dryness, the Tangible Hydra-PEG is a high-water polymer coating that is bonded to the surface of a contact lens. In June 2018, Bausch + Lomb entered into a worldwide licensing agreement with Tangible Science to offer the Tangible Science Hydra-PEG advanced contact lens coating technology on specific materials and lenses from its specialty contact lens business.

  • 15

    Feb

  • 20

    Feb

  • 20

    Feb

  • 25

    Feb

BHC Bausch Health
$25.33

0.235 (0.94%)

01/02/19
PIPR
01/02/19
UPGRADE
Target $27
PIPR
Overweight
Bausch Health upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray analyst David Amsellem upgraded Bausch Health Companies to Overweight from Neutral and raised his price target for the shares to $27 from $22. The company formerly known as Valeant Pharmaceuticals closed Monday down 32c to $18.47. The analyst says that while he's been "unrelentingly negative" on the company for years, it is time to "turn the page following a closer look at the business." Management has positioned Bausch not only for longer-term EBITDA stability, but potentially "meaningful" growth, Amsellem tells investors in a research note. While the company is still highly levered, a favorable maturity schedule gives it "ample breathing room," and strong visibility into EBITDA stability/growth should enable the company to "chip away significantly at debt levels in the coming years," says the analyst. He thinks Bausch Health's valuation is positioned for multiple expansion over time.
01/02/19
PIPR
01/02/19
NO CHANGE
PIPR
Piper calls Horizon top 2019 growth idea in Specialty Pharmaceuticals
Piper Jaffray analyst David Amsellem calls Horizon Pharma (HZNP) his top "growth oriented/GARP idea" for 2019. The company offers high asset quality, visibility into significant longer-term EBITDA growth, and manageable debt levels that enable significant business development flexibility, Amsellem tells investors in a research note. He believes the Specialty Pharmaceuticals group is well positioned to perform more in-line with the broader therapeutics and overall healthcare spaces in 2019, or "certainly better than what we have seen in recent years." The analyst names Bausch Health (BHC), a stock he upgraded this morning to Overweight, his top "de-leveraging/defensive pick" for 2019. Further, Amsellem's top "development-stage picks" for 2019 are Cara Therapeutics (CARA) and Revance Therapeutics (RVNC).
01/02/19
01/02/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Bausch Health (BHC) upgraded to Overweight from Neutral at Piper Jaffray with analyst David Amsellem saying while he's been "unrelentingly negative" on the company for years, it is time to "turn the page following a closer look at the business." 2. Crocs (CROX) and Shoe Carnival (SCVL) were upgraded to Positive from Neutral at Susquehanna. 3. Stryker (SYK) upgraded to Outperform from In Line at Evercore ISI. 4. CBS (CBS) upgraded to Overweight from Equal Weight at Stephens with analyst Kyle Evans saying he believes investor sentiment is poised to improve on the name in 2019 and that the company can continue to post solid results driven by underlying unit growth and stronger pricing. 5. Sirius XM (SIRI) upgraded to Overweight from Neutral at JPMorgan with analyst Sebastiano Petti saying Sirius XM shares are attractively following the 25% pullback from the 2018 highs. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/10/19
PIPR
01/10/19
NO CHANGE
Target $27
PIPR
Overweight
Piper sees Bausch Health as 'stand out' after management meeting
Piper Jaffray analyst David Amsellem reiterates an Overweight rating on Bausch Health Companies with a $27 price target after meeting with management. The analyst says commentary from the company reinforced his view that Bausch will continue to "stand out among the broader group of highly-levered specialty pharma names." Management has high visibility into not only longer-term EBITDA stability but meaningful long-term growth, Amsellem tells investors in a research note. Significant growth from the gastroenterology franchise along with modest growth from the dermatology and eye care segments should translate into a long-term annual EBITDA growth at least in the mid-single digits, says the analyst.

TODAY'S FREE FLY STORIES

LTN

Union Acquisition Corp

$5.89

-1.44 (-19.65%)

12:00
02/22/19
02/22
12:00
02/22/19
12:00
Hot Stocks
Union Acquisition Corp falls -17.3% »

Union Acquisition Corp is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

TDS

Telephone and Data

$32.14

-4.55 (-12.40%)

12:00
02/22/19
02/22
12:00
02/22/19
12:00
Hot Stocks
Telephone and Data falls -12.5% »

Telephone and Data is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

DPLO

Diplomat Pharmacy

$7.65

-5.81 (-43.16%)

12:00
02/22/19
02/22
12:00
02/22/19
12:00
Hot Stocks
Diplomat Pharmacy falls -42.9% »

Diplomat Pharmacy is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 11

    Mar

  • 12

    Mar

PBI

Pitney Bowes

$8.25

1.225 (17.45%)

12:00
02/22/19
02/22
12:00
02/22/19
12:00
Hot Stocks
Pitney Bowes rises 17.4% »

Pitney Bowes is up 17.4%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

  • 28

    Mar

SWM

Schweitzer-Mauduit

$41.20

6.51 (18.77%)

12:00
02/22/19
02/22
12:00
02/22/19
12:00
Hot Stocks
Schweitzer-Mauduit rises 19.0% »

Schweitzer-Mauduit is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

  • 28

    Mar

W

Wayfair

$153.23

36.09 (30.81%)

12:00
02/22/19
02/22
12:00
02/22/19
12:00
Hot Stocks
Wayfair rises 30.9% »

Wayfair is up 30.9%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

  • 03

    Mar

CAG

Conagra Brands

$23.13

-0.95 (-3.95%)

11:55
02/22/19
02/22
11:55
02/22/19
11:55
Options
ConAgra put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:55
02/22/19
02/22
11:55
02/22/19
11:55
General news
FX Action: USD-CAD »

FX Action: USD-CAD has…

11:55
02/22/19
02/22
11:55
02/22/19
11:55
Conference/Events
William Blair medical tech analyst to hold a luncheon »

Medical Technology &…

TKR

Timken

$43.82

0.41 (0.94%)

11:51
02/22/19
02/22
11:51
02/22/19
11:51
Conference/Events
Timken management to meet with KeyBanc »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

KPTI

Karyopharm

$8.97

0.01 (0.11%)

11:50
02/22/19
02/22
11:50
02/22/19
11:50
Recommendations
Karyopharm analyst commentary  »

H.C. Wainwright sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 28

    Feb

  • 06

    Apr

JEC

Jacobs Engineering

$74.22

0.45 (0.61%)

11:48
02/22/19
02/22
11:48
02/22/19
11:48
Conference/Events
Jacobs Engineering management to meet with KeyBanc »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 12

    Mar

TCDA

Tricida

$23.11

0.84 (3.77%)

11:46
02/22/19
02/22
11:46
02/22/19
11:46
Initiation
Tricida initiated  »

Tricida initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UPS

UPS

$109.87

-1.89 (-1.69%)

11:45
02/22/19
02/22
11:45
02/22/19
11:45
Options
UPS call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

11:45
02/22/19
02/22
11:45
02/22/19
11:45
General news
More from Williams: the Phillips Curve needs to be taken seriously »

More from Williams: the…

OCUL

Ocular Therapeutix

$4.22

0.61 (16.90%)

11:37
02/22/19
02/22
11:37
02/22/19
11:37
Hot Stocks
Ocular Therapeutix higher after pricing $37.5M in convertible notes »

Shares of Ocular…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:35
02/22/19
02/22
11:35
02/22/19
11:35
General news
The Fed's Monetary Policy Report »

The Fed's Monetary…

AXNX

Axonics

$21.65

-0.85 (-3.78%)

11:33
02/22/19
02/22
11:33
02/22/19
11:33
Hot Stocks
Axonics granted expanded CE mark label approval for Axonics r-SNM System »

Axonics Modulation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Mar

  • 05

    Mar

EA

Electronic Arts

$95.01

-1.825 (-1.88%)

11:30
02/22/19
02/22
11:30
02/22/19
11:30
Options
Buyer pays $3.3M for EA upside calls as shares drop 2% »

Buyer pays $3.3M for EA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

VLKAY

Volkswagen

$0.00

(0.00%)

11:27
02/22/19
02/22
11:27
02/22/19
11:27
Periodicals
VW CEO says he hopes company did enough 'to avoid import taxes', CNBC reports »

Volkswagen CEO Herbert…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$19.10

1.68 (9.64%)

11:25
02/22/19
02/22
11:25
02/22/19
11:25
Options
Amarin call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

MDT

Medtronic

$93.25

0.65 (0.70%)

11:25
02/22/19
02/22
11:25
02/22/19
11:25
Conference/Events
Medtronic participates in a conference call with JPMorgan »

Healthcare Analyst Marcus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 25

    Feb

  • 06

    Mar

  • 18

    May

  • 28

    May

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
02/22/19
02/22
11:17
02/22/19
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
02/22/19
02/22
11:16
02/22/19
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:15
02/22/19
02/22
11:15
02/22/19
11:15
General news
Fed's Daly said the Fed should aim to hit the 2% inflation target on average »

Fed's Daly said the…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.